Systemic Lupus Erythematosus (SLE) Clinical Trial
Official title:
An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE)
CAR-T therapy was therefore proposed and has been recently used for cancer treatment. It has been hailed for its promising remission rates after early stage clinical trials for acute lymphoblastic leukemia. However, CAR-T therapy is seldom used for autoimmune diseases. Researchers only use it for the treatment of multiple sclerosis (MS, an autoimmune disease of the central nervous system). SLE is a kind of autoimmune diseases which involving multiple systems, organs and with the present of a variety of autoantibodies. In the conventional treatment options, SLE could be treated with chemotherapy drugs or hormone drugs. But chemotherapy and hormone drugs could barely cured SLE. And now, chimeric antigen receptor modified T cell infusion maybe an effective treatment to solve these problems. The investigators use a 2nd CAR- T with the optimized hinge and transmembrane domain to treat patients with SLE. The purpose of this study is to assess the safety and efficacy of this 2nd CAR-T cells in the treatment of SLE.
This study is being conducted to assess anti-CD19-CAR-T cells safety and efficacy in treating patients with systemic lupus erythematosus（SLE）.The investigators constructed a 2nd CAR, using CD19 as target, using 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge and transmembrane domain sequences. The infusion dose is (1-10)E6 CAR positive T cells/kg, and the specific cells numbers depends on the situation of individual CAR-T cells preparation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04461158 -
CCCR Lupus Patient Navigator Program
|
N/A | |
| Completed |
NCT02006784 -
Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Completed |
NCT01072734 -
Auto-immunity in Lupus Patients After Influenza Vaccine
|
Phase 2 | |
| Completed |
NCT03626311 -
Omega-3 Replacement With Krill Oil in Disease Management of SLE
|
N/A | |
| Withdrawn |
NCT02779153 -
Acthar SLE (Systemic Lupus Erythematosus)
|
Phase 4 | |
| Completed |
NCT01992666 -
GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus
|
N/A | |
| Completed |
NCT00779194 -
Prospective Study of Rapamycin for the Treatment of SLE
|
Phase 2 | |
| Recruiting |
NCT00582881 -
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
|
||
| Terminated |
NCT02811094 -
LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse
|
N/A | |
| Recruiting |
NCT05458622 -
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
|
Phase 3 | |
| Recruiting |
NCT06144710 -
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
|
Phase 1 | |
| Completed |
NCT03031925 -
Detection of Annexin A2 in Systemic Lupus Erythematosus
|
N/A | |
| Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
| Recruiting |
NCT02782039 -
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
|
||
| Recruiting |
NCT05567198 -
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
|
||
| Recruiting |
NCT05747651 -
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
|
||
| Recruiting |
NCT06249438 -
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT05724940 -
Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
|
||
| Recruiting |
NCT06032923 -
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
|
Phase 1/Phase 2 | |
| Completed |
NCT03122431 -
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
|
Phase 4 |